Kuznicki Law is investigating the proposed merger of Reneo Pharmaceuticals, Inc. (NasdaqGM: RPHM) (the “Company”) and OnKure, Inc. Upon completion of the proposed transaction, pre-merger Reneo shareholders are expected to own approximately 31% of the combined company. Kuznicki Law is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to Reneo shareholders.
Reneo Pharmaceuticals, Inc. (NasdaqGM: RPHM) Loss Submission Form
If you would like to discuss your legal rights regarding this case, you may, without obligation or cost to you, contact us toll free at (833) 835-1495 or fill out the loss submission form on this page.